Fridays at 10 am
Covering the outer reaches of space to the tiniest microbes in our bodies, Science Friday is the trusted source for news about science, technology, and other cool stuff. Host Ira Flatow mixes it up by featuring people in the know and those who want to be. Science Friday frequently features listeners that call in with their most riveting science questions. In addition, Science Friday also produces award-winning videos. It's brain fun, for curious people.
Friday, June 18, 2021 9:52am
COVID-19 Vaccines May Not Protect Immunocompromised People
This week, California and New York, two of the states hardest hit by the COVID-19 pandemic, announced that they were relaxing almost all coronavirus-related business restrictions. Across the country, vaccination numbers are slowly ticking up—although a troubling COVID-19 variant known as Delta is picking up as well. As things reopen, experts warn that people with compromised immune systems may not be well protected, even if they do get the vaccine.
There are many reasons someone might have a weakened immune system, including an illness, cancer treatment, or the use of immune-suppressing drugs needed for an organ transplant. But regardless of the reason, immunocompromised people may not be able to mount a strong antibody response to the vaccines.
Dr. John Mellors, chief of the division of infectious diseases at the University of Pittsburgh Medical Center, and Dr. Lindsay Ryan, an internist at UCSF in San Francisco who is herself immunocompromised, talk with Ira about what we know about the performance of COVID-19 vaccines in immunocompromised people, and what people with weakened immune systems can do to help protect themselves against the illness.
The Best Sci-Fi Books To Read This Summer
Whether you’ve had a hard time reading during the pandemic, or you zoomed through your book pile and are craving more, Science Friday’s annual list of the best summer science books is here for you.
As the world begins to open up, many of us are not quite comfortable traveling like we once did. But what a better way to escape without going too far than by immersing ourselves in some science fiction? Hit the beach—and another dimension, travel to space from the safety of your backyard, or take a hike back in time to an alternate era.
And this summer we tapped two sci-fi aficionados to help build our list. Annale Newitz, science journalist and author of Four Lost Cities, and Gretchen Treu, co-owner of A Room of One’s Own Bookstore, in Madison Wisconsin, share their superb summer selections with Ira in front of a live Zoom audience.
Friday, June 18, 2021 9:50am
How To Talk About Medical Marijuana With Your Doctor
Over the last decade, cannabis has had a moment. Thirty-six states and Washington D.C. have legalized it for medical use. (Fifteen states, plus D.C., have also legalized weed recreationally.) Altogether, about 5.5 million people in the U.S. now have medical marijuana cards.
One of the primary arguments for expanding marijuana laws is the drug’s potential usefulness for medical treatments. While each state has its own rules for which conditions are eligible, issues like chronic pain are nearly universally accepted as a reason for using medical marijuana.
But there’s still a large divide between the traditional medical establishment and the cannabis industry. Cannabis is still illegal federally, and a recent study showed that many clinicians feel they don’t know enough about medical marijuana to make a recommendation to patients. This in turn impacts how patients feel about talking to their doctor about using cannabis to treat medical conditions.
Joining Ira to talk about the ins and outs of connecting cannabis to the larger medical establishment are Dr. Ziva Cooper, research director for UCLA’s Cannabis Research Initiative in San Francisco, California, and Dr. Donald Abrams, integrative oncologist and professor emeritus at University of California San Francisco’s Osher Center for Integrative Medicine.
What Can Crayfish Tell Us About Drugs In Our Waterways?
Wastewater is a grab bag of chemicals. There’s industrial run-off, bits of animal and viral DNA, and then there are compounds that trickle out from our households. The medicines we’re flushing down the toilet or releasing through urine are making their way into countless bodies of water.
Antidepressants are one of the drugs that frequently end up in the environment. A team of scientists wanted to study the effects of these antidepressants on streams wending their way through ecosystems. So they looked to none other than the crayfish. They found that crayfish exposed to these drugs were a bit bolder. Their results were published this week in the journal Ecosphere. Freshwater ecologist Lindsey Reisinger and freshwater biogeochemist A.J. Reisinger, who are both authors on that study, talk about how these drugs affect crayfish and potential downstream effects on waterways and the ecosystem.
We Aren’t Squidding Around—It’s Cephalopod Week 2021!
The wait is over—Cephalopod Week 2021 is finally here. It’s Science Friday’s annual ceph-lo-bration of all things mostly-tentacled, and this year’s lineup of events is going to be ceph-tacular.
Diana Montano, SciFri’s outreach manager and emcee of the deep sea, joins Ira and Science Diction host Johanna Mayer to kick things off, with some trivia about the origins of squiddy words.
Kids Are Benefiting From Adult Vaccinations, Too
Something interesting is happening in some communities where most adults are vaccinated against COVID-19: infection rates in kids are going way down, too. Right now, Americans 12 and older are eligible for the vaccine, leaving the country’s youngest still exposed. So this is a promising sign, considering about two-thirds of U.S. adults have received at least one shot of a COVID-19 vaccine.
But some experts are saying we still need to be cautious about throwing kids together again before they’re vaccinated. Joining Ira to chat about this story is Maggie Koerth, senior science writer at FiveThirtyEight in Minneapolis, Minnesota. They also talk about other top science stories of the week, including news that cicada broods might emerge more often with climate change.
Friday, June 11, 2021 9:27am
Biden’s New Assistant Secretary Of Health On Protecting Trans Youth
The American healthcare system is facing some incredible challenges: Black and Latino communities were hit harder by COVID-19, and have lower vaccination rates than white, Asian, and Native American communities. The opioid crisis is still raging, climate change is disproportionately impacting the health of communities of color, and a wave of anti-trans healthcare bills are being pushed by Republican lawmakers through multiple states.
Dr. Rachel Levine, President Biden’s appointee for assistant secretary of health for the department of Health and Human Services, is aiming to take on all of that, and more. She previously served as Pennsylvania’s secretary of health and physician general, combating both the opioid and COVID-19 crises there. Now, she wants to scale those efforts to a federal level, in addition to helping meet President Biden’s goal of getting 70% of adults with at least one vaccine dose by July 4. She also made history as the highest-ranking, openly transgender person to have served in the federal government.
Levine talks to Ira about the steps needed to achieve health equity, advocating for the healthcare rights of trans youth and adults, and her ambitions for her time in office.
Why Oxen Were The Original Robots
In media and pop culture narratives about robotic futures, two main themes dominate: there are depictions of violent robot uprisings, like the Terminator. And then there are those that circle around the less deadly, more commonplace, fear that machines will simply replace humans in every role we excel at.
There is already precedent for robots moving into heavy lifting jobs like manufacturing, dangerous ones like exploring outer space, and the most boring of administrative tasks, like computing. But roboticist Kate Darling would like to suggest a new narrative for imagining a better future—instead of fighting or competing, why can’t we be partners?
The precedent for that, too, is already here—in our relationships with animals. As Darling writes in The New Breed: What Our History With Animals Reveals About Our Future With Robots, robotic intelligence is so different from ours, and their skills so specialized, that we should envision them as complements to our own abilities. In the same way, she says, a horse helps us travel faster, pigeons once delivered mail, and dogs have become our emotional companions.
Darling speaks with Ira about the historical lessons of our relationships with animals, and how they could inform our legal, ethical, and even emotional choices about robots and AI.
Friday, June 11, 2021 9:27am
FDA’s Approval Of Debated Alzheimer’s Treatment Raises Controversy
This week, the FDA gave the green light to a drug for the treatment of Alzheimer’s disease. The drug, a monoclonal antibody called aducanumab, is the first Alzheimer’s treatment to receive approval in almost 20 years. It targets the amyloid protein that forms the tangled plaques found in the brains of people with Alzheimer’s. But while researchers agree that aducanumab leads to less amyloid plaque, no one really knows what that means in terms of real benefits for people with the disease.
Researchers still don’t understand the role of amyloid in the progression of Alzheimer’s disease—and in two studies conducted by the company Biogen, only one showed taking aducanumab provided a slight cognitive benefit to people with early Alzheimer’s. The other study showed no effect compared to a placebo. However, the FDA elected to ignore the recommendations of an outside advisory panel, and approved the medication under an accelerated approval process. The drugmaker will be required to conduct additional testing on the treatment while it is on the market, and the FDA has the option to rescind approval if a Phase 4 trial fails to show efficacy.
Biogen will sell the treatment under the trade name Aduhelm, at a list price of around $56,000 per year—not including the extensive office visits, tests, brain scans, and monitoring that will go along with the course of treatment. Pam Belluck, a writer covering science and medicine for the New York Times, joins host John Dankosky to explain the decision, and how the drug might fit into the larger picture of Alzheimer’s research.
When Scientists Get It Wrong
A couple of years ago, Julia Strand was trying and failing to replicate a study she’d published. At the time, she was an assistant professor without tenure, and the original study had presented her most exciting finding to date. But when she and her co-authors tried to replicate it, they got the opposite results. Then one night, Julia discovered why. In her original code, she’d made a tiny but critical error, and now, with her reputation and job on the line, she was going to have to tell the world about it.
Science is often said to be “self-correcting”—through peer review, replication, and community dialogue, scientists collectively find mistakes in their work, and continually revise their understanding of the world. But what does self-correction look like in practice? And how likely are scientists to admit they’re wrong?
Julia eventually submitted her story to the Loss of Confidence Project, which invited psychologists to publicly admit mistakes in their published research. Our guest, Julia Roher, a lecturer in psychology, organized the project, along with two others. In an anonymous survey of 316 researchers, almost half said they had lost confidence in one of their findings, but ultimately, only 13 researchers submitted public testimonials to the project.
Brian Resnick, who co-created Vox’s Unexplainable podcast and has written about intellectual humility, explains why we often think we’re right when we’re wrong, how others perceive us when we fess up to mistakes, and what all this means for our trust in science.
Charismatic Creature Corner: Chonky Fish Edition
In South Africa in 1938, a young museum curator named Marjorie Courtenay-Latimer was performing one of her regular duties when she saw something incredible. Courtenay-Latimer was tasked with inspecting fish brought in by local fishermen that were considered out of place in the region. That’s how she found what she later called the most beautiful fish she had ever seen: a coelacanth, thought to be long extinct.
Courtenay-Latimer’s discovery did not immediately register as a coelacanth, because the creature was thought to have gone extinct at the end of the Cretaceous period, 66 millions years ago. The fish was seen as a modern Lazarus—a mysterious creature brought back from the dead, stumping scientists.
At six feet long and 200 pounds, some consider the coelacanth to be a big, beautiful fish. According to Dr. Prosanta Chakrabarty, professor and curator of fishes at Louisiana State University, the coelacanth is the meathead of the sea.
“They are chunky,” Chakrabarty said. “You can hold their fin and it feels like you’re shaking somebody’s hand.”
Because they’re so old, coelacanths are closer to the human genealogical lineage than they are to any modern fish. But because this is the Charismatic Creature Corner, only one thing really matters: Is it charismatic enough to enter the Charismatic Creature Corner Hall of Fame?
Joining guest-host John Dankosky to argue for the coelacanth entering the Charismatic Creature Corner Hall of Fame is SciFri producer Kathleen Davis and Dr. Chakrabarty.
Friday, June 4, 2021 11:25am
Research Reveals 178 Genes Are Associated With Depression
If you have a family member that suffers from depression, chances are you may have more than one. Doctors often say “depression runs in families,” but scientists really had no good idea how—until a major analysis of the genomes of 200,000 military veterans uncovered the 178 genes that influence your risk of major depression.
Science Friday producer Katie Feather talked to Dr. Daniel Levey, assistant professor of psychiatry at Yale University School of Medicine. He explains why there are so many associated genes, and more about the massive database that helped scientists find them.
Can Genetic Engineering Help Humans Live In Space?
The next ambitious goal for space flight is to send a human to Mars. After decades of sending space probes and rovers, there are now actual plans for human voyages. Elon Musk says the deadline for Space X’s Mars Mission may be as early as 2024.
This raises big questions, both about how to survive the trip, and then inhabit a world hostile to humans. In his new book, The Next 500 Years: Engineering Life to Reach New Worlds, geneticist Christopher Mason says the biggest technical challenges could be met by genetically engineering humans to survive long-term space living.
He is joined by astronaut Scott Kelly, who spent one year in space, to talk about how we might genetically engineer ourselves, and the effects that space flight has on the body.
How Might Technology Shift Our Morality?
What is right, and what is wrong? Today’s debates range from the ethics of eating meat, to abortion rights. Conversely, some questions are much less contentious than they once were: we no longer debate whether abducting and enslaving human beings is wrong—it is. And we no longer question technologies like in vitro fertilization.
Author Juan Enriquez says we can thank technological changes for modern shifts in ethical rights and wrongs, from energy technologies that reduce the value of manual labor to social media that boosts the visibility of LGBTQ people. Enriquez writes that technology changes over history have—and will continue to—change the nature of what we consider right and wrong.
As he writes in Right/Wrong: How Technology Transforms Ethics, published in 2020, scientific advances in genetic engineering and neuroscience are bound to shift our ethical conversations even further. Think about CRISPR-edited genomes, or the potential privacy violations posed by being able to interpret brain activity. Climate change, and how to combat it, also raises important ethical questions.
Enriquez talks to Ira about his work, and what he predicts our future ethical quandaries might look like.